Skip to main content
Toggle menu

Search the website

Status:
Published
Posted:

Pregabalin: what the patent litigation means for doctors and drug companies

Explaining the arguments over the Pregabalin patent case and explore the wider implications for the NHS and drug development

BMJ, 2018

Darren Smyth, Richard Croker, and Ben Goldacre explain the arguments over the patent case and explore the wider implications for the NHS and drug development

Authors
Citation
Smyth D, Croker R, Goldacre B. Pregabalin: what the patent litigation means for doctors and drug companies BMJ 2018; 361 :k2318
Categories